Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the target of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 6,880,000 shares, a growth of 19.4% from the January 15th total of 5,760,000 shares. Based on an average daily volume of 2,010,000 shares, the short-interest ratio is currently 3.4 days.

Adaptimmune Therapeutics Trading Up 1.6 %

Shares of ADAP traded up $0.01 during mid-day trading on Tuesday, hitting $0.59. 449,443 shares of the company's stock traded hands, compared to its average volume of 988,352. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The business's 50-day moving average price is $0.59 and its 200-day moving average price is $0.80. Adaptimmune Therapeutics has a 1 year low of $0.53 and a 1 year high of $2.05. The firm has a market capitalization of $150.20 million, a P/E ratio of -2.67 and a beta of 2.42.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Long Focus Capital Management LLC raised its stake in shares of Adaptimmune Therapeutics by 54.1% in the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company's stock worth $11,040,000 after purchasing an additional 7,194,503 shares during the last quarter. Baillie Gifford & Co. raised its stake in shares of Adaptimmune Therapeutics by 10.7% in the third quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company's stock worth $15,944,000 after purchasing an additional 1,626,657 shares during the last quarter. Two Seas Capital LP purchased a new position in shares of Adaptimmune Therapeutics in the fourth quarter worth $7,992,000. Renaissance Technologies LLC increased its position in Adaptimmune Therapeutics by 52.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock worth $1,361,000 after buying an additional 869,949 shares in the last quarter. Finally, Rock Springs Capital Management LP increased its position in Adaptimmune Therapeutics by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock worth $1,338,000 after buying an additional 58,000 shares in the last quarter. 31.37% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ADAP has been the topic of a number of analyst reports. Guggenheim decreased their price target on Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday, November 15th. Mizuho decreased their price target on Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating on the stock in a research note on Wednesday, November 27th. StockNews.com cut Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, November 14th. Finally, HC Wainwright decreased their price target on Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating on the stock in a research note on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Adaptimmune Therapeutics has a consensus rating of "Buy" and an average price target of $2.79.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.